Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: A case report

被引：3
作者：
Vitale M.G. [1 ]
Riccardi F. [1 ]
Mocerino C. [1 ]
Barbato C. [1 ]
Monaco R. [2 ]
Galloro P. [2 ]
Gagliardi N. [3 ]
Cartenì G. [1 ]
机构：
[1] UOSC Oncologia, Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Naples
[2] UOSC Anatomia Patologica, Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Naples
[3] UOSC Radiologia, Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli, Naples
来源：
Journal of Medical Case Reports | / 8卷 / 1期
关键词：
EGFR amplification; EGFR mutation; erlotinib; Second-line treatment in NSCLC;
D O I：
10.1186/1752-1947-8-102
中图分类号：
学科分类号：
摘要：
Introduction. The efficacy of erlotinib in advanced non-small-cell lung cancer has been demonstrated in several trials, but only two cases of complete and prolonged response in wild-type epidermal growth factor receptor locally advanced lung cancer have been published. Case presentation. We discuss a case of a 67-year-old Caucasian man, a former heavy cigarette smoker, with a diagnosis of wild-type epidermal growth factor receptor locally advanced adenocarcinoma. After platinum-based doublet chemotherapy, when a progression of disease had occurred, a second-line therapy with erlotinib was started. We observed a progressive reduction of his lung lesion during erlotinib treatment until there was a complete clinical response. Conclusions: This case is interesting for the choice of second-line treatment in non-small-cell lung cancer and, moreover, for the possibility of a complete and prolonged response to erlotinib even in patients without the activating mutation of epidermal growth factor receptor. © 2014 Vitale et al.; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 22 条
  • [1] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D., Global cancer statistics, CA Cancer J Clin, 61, pp. 69-90, (2011)
  • [2] Peters S., Adjei A.A., Gridelli C., Reck M., Kerr K., Felip E., Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 23, SUPPL. 7, (2012)
  • [3] Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., Zhang S., Wang J., Zhou S., Ren S., Lu S., Zhang L., Hu C., Hu C., Luo Y., Chen L., Ye M., Huang J., Zhi X., Zhang Y., Xiu Q., Ma J., Zhang L., You C., Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, pp. 735-742, (2011)
  • [4] Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., Palmero R., Garcia-Gomez R., Pallares C., Sanchez J.M., Porta R., Cobo M., Garrido P., Longo F., Moran T., Insa A., De Marinis F., Corre R., Bover I., Illiano A., Dansin E., De Castro J., Milella M., Reguart N., Altavilla G., Jimenez U., Provencio M., Moreno M.A., Terrasa J., Munoz-Langa J., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small
  • [5] Shepherd F.A., Pereira J.R., Ciuleanu T., Eng H.T., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., Van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabarbara P., Seymour L., Erlotinib in previously treated non-small-cell lung cancer, New England Journal of Medicine, 353, 2, pp. 123-132, (2005)
  • [6] Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczesna A., Juhasz E., Esteban E., Molinier O., Brugger W., Melezinek I., Klingelschmitt G., Klughammer B., Giaccone G., Saturninvestigators, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study, Lancet Oncol, 11, 6, pp. 521-529, (2010)
  • [7] Seer.cancer.gov [Internet]
  • [8] Burdett S., Stewart L., Pignon J.P., Chemotherapy in non-small cell lung cancer: An update of an individual patient data-based meta-analysis, J Thorac Cardiovasc Surg, 129, (2005)
  • [9] Burdett S., Stephens R., Stewart L., Tierney J., Auperin A., Le Chevalier T., Le Pechoux C., Pignon J.P., Arriagada R., Higgins J., Johnson D., Van Meerbeeck J., Parmar M., Souhami R., Bell D., Cartei G., Cormier Y., Cullen M., Ganz P., Gridelli C., Kaasa S., Quoix E., Rapp E., Seymour L., Spiro S., Thatcher N., Tummarello D., Williams C., Williamson I., Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of
  • [10] Gridelli C., Bareschino M.A., Schettino C., Rossi A., Maione P., Ciardiello F., Erlotinib in non-small cell lung cancer treatment: Current status and future development, Oncologist, 12, 7, pp. 840-849, (2007)
123